Welcome to our dedicated news page for Acumen Pharmaceuticals (Ticker: ABOS), a resource for investors and traders seeking the latest updates and insights on Acumen Pharmaceuticals .
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Acumen Pharmaceuticals 's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Acumen Pharmaceuticals 's position in the market.
Rhea-AI Summary
Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) reported financial results for Q3 2023 and provided a business update. They announced the initiation of a Phase 2 study, ALTITUDE-AD, to investigate ACU193 for the treatment of early Alzheimer’s disease in the first half of 2024, following positive FDA interaction. A global collaboration and license agreement with Halozyme for development of a subcutaneous formulation of ACU193 was announced. Additionally, a Phase 1 study to support a subcutaneous dosing option of ACU193 is expected in mid-2024. Acumen also secured a credit facility of up to $50 million from K2 HealthVentures to support subcutaneous clinical work and general corporate purposes. CSF biomarker data observed in the Phase 1 INTERCEPT-AD trial support the pharmacology of ACU193 and its role in Alzheimer’s disease. The company has cash, cash equivalents, and marketable securities of $282.7 million as of Sept. 30, 2023, expected to support current clinical and operational activities into the second half of 2026. They will host a conference call and webcast at 8:00 a.m. ET today.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.84%
Tags
-
Rhea-AI Summary
Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) secures a $30 million senior secured loan from K2 HealthVentures to support the development of a subcutaneous formulation of ACU193 for Alzheimer's disease treatment. The funding will also be used for general corporate purposes. The loan consists of a first tranche of $30.0 million, with a potential second tranche of up to $20.0 million. The Term Loan matures on November 1, 2027, and may be extended to November 1, 2028, subject to certain milestones.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.84%
Tags
-
Rhea-AI Summary
Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) to participate in fireside chat at Stifel Healthcare Conference on Nov. 14, 2023, to discuss novel therapeutic for Alzheimer’s disease
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.39%
Tags
Rhea-AI Summary
Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) will report third quarter financial results on Nov. 13, 2023. The company is developing a novel therapeutic for Alzheimer's disease. A conference call and live webcast will be held at 8:00 a.m. ET for a business and financial update. Registration is required to participate.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.48%
Tags
-
Rhea-AI Summary
Acumen Pharmaceuticals has announced a collaboration and license agreement with Halozyme Therapeutics to develop a subcutaneous formulation of ACU193, an antibody for the treatment of Alzheimer's disease. The collaboration will provide Acumen access to Halozyme's ENHANZE® drug delivery technology. Acumen plans to initiate Phase 1 development in mid-2024 to compare the pharmacokinetics of the subcutaneous form to the intravenous form.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.02%
Tags
-
Rhea-AI Summary
Acumen Pharmaceuticals, Inc. will participate in a fireside chat at the UBS Biopharma Conference on Nov. 9, 2023. The company is developing a therapeutic for Alzheimer's disease targeting toxic soluble amyloid beta oligomers.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.73%
Tags
Rhea-AI Summary
Acumen Pharmaceuticals presents further analyses of the Phase 1 INTERCEPT-AD trial evaluating ACU193, the first clinical-stage AβO-targeting antibody. The analyses reveal robust target engagement data modeling informing dose selection for the upcoming Phase 2/3 trial. New target engagement and pharmacokinetic analyses were also presented. Acumen plans to begin the Phase 2 portion of the study in the first half of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-24.84%
Tags
-
Rhea-AI Summary
Acumen Pharmaceuticals will present deeper insights and new findings from its Phase 1 INTERCEPT-AD trial evaluating ACU193 at the CTAD conference. ACU193 demonstrated a compelling overall safety profile and potential clinical benefit for early AD. The presentation will include data on dose-related target engagement, amyloid plaque reduction, and ARIA levels observed with ACU193 administration. The company believes ACU193 may offer a differentiated, next-generation treatment for Alzheimer's disease.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.71%
Tags
-
Rhea-AI Summary
Acumen Pharmaceuticals to participate in panel discussion at Cantor Global Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.73%
Tags
News
Rhea-AI Summary
Acumen Pharmaceuticals to present at H.C. Wainwright conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.4%
Tags
Acumen Pharmaceuticals, Inc.
Nasdaq:ABOS
ABOS Rankings
ABOS Stock Data
195.26M
32.28M
9.13%
72.62%
2.06%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
United States of America
CHARLOTTESVILLE
About ABOS
acumen is forging a new path towards safe and effective treatments for alzheimer’s disease and other neurodegenerative diseases through our focus on the biology of toxic amyloid-beta oligomers. our founders pioneered seminal discoveries and methods to understand the role of toxic amyloid-beta oligomers (aβo) in synaptic dysfunction and neurodegeneration. these early insights have fostered decades of research on the biology of aβo at acumen and throughout the field. we are now on the on cusp of realizing the therapeutic potential of aβo targeted drugs.